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Abstract
Background: The aims of this report were to describe a case of ovarian adenosquamous carcinoma and to
systematically review the pertinent literature.
Methods: We describe a case in which a 57-year-old woman had stage IC ovarian cancer histologically diagnosed
as adenosquamous carcinoma. We also systematically reviewed the literature using the PubMed database.
Case Presentation: Preoperative computed tomography and magnetic resonance imaging showed a tumor
measuring 14 cm in diameter and containing solid areas. Tumor marker levels were as follows: CA125, 42.6 U/mL;
CA 19–9, 134.1 U/mL; CEA, 0.9 ng/mL; and SCC, 1.6 ng/mL. The patient underwent multiple surgeries including total
abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection, para-aortic lymph node
biopsy, and total omentectomy. Based on the cytological features of the ascitic fluid, the tumor was diagnosed as a
squamous cell carcinoma. Histological examination of an excised specimen showed the transition of an
endometrioid adenocarcinoma to a squamous cell carcinoma. There was no evidence of any teratomas or
endometriosis-related features. We considered the tumor to be an adenosquamous carcinoma, with the squamous
cell carcinoma component arising from the endometrioid adenocarcinoma component. After surgery, the patient
underwent 6 cycles of paclitaxel and carboplatin chemotherapy. There has been no recurrence to date, 66 months
after the initial treatment.
Results: Histologically, the 8 adenosquamous carcinomas reported in the literature either arose from the mature
cystic teratoma (4 cases) or endometriosis (3 cases) or were pure adenosquamous carcinomas (1 case). Our
literature search uncovered no cases of ovarian adenosquamous carcinomas originating from endometrioid
adenocarcinomas.
Conclusions: This is the first reported case of an adenosquamous carcinoma arising from an endometrioid
adenocarcinoma. Because such tumors are rare, their standard management is unclear.
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Background
Various types of primary and metastatic tumors occur in
the ovaries. Squamous cell carcinoma of the ovary is, how-
ever, rare, and adenosquamous carcinomas account for
less than 1 % of all ovarian malignancies [1]. Conditions
leading to the development of an adenosquamous carcin-
oma include malignant transformation of a preexisting
ovarian teratoma [2, 3] and endometriosis [4]. In addition,
endometrioid adenocarcinomas contain squamous com-
ponents, which may become malignant. Herein we report
a case of adenosquamous carcinoma that did not involve a
preexisting teratoma or endometriosis. Based on the histo-
pathological findings, we believe this tumor arose from
the squamous metaplasia of an endometrioid adenocarcin-
oma. We describe this tumor and its histology in the con-
text of previously reported cases obtained from a
systematic review of the literature [1–7].
Methods of literature review
We searched the PubMed database (up to November
2015) using, among others, the key words “adenosquamous
carcinoma” and “ovary.” Our search generated 53 articles;
those not written in English (7 in Japanese, 3 in Chinese,
and 1 each in Portuguese, Spanish, Bulgarian, and French)
were excluded. Of the remaining 39 articles, 27 were
excluded because the histological type was squamous cell
carcinoma or endometrioid adenocarcinoma or because
the cancer described was not ovarian (e.g., cervical cancer,
endometrial cancer, or fallopian tube carcinoma). Of the 12
articles describing ovarian adenosquamous carcinomas,
only 5 determined the histological origin of the carcinoma.
The references cited by the 2 articles retrieved were also
reviewed; ultimately, 7 articles reporting 8 cases are dis-
cussed herein [1–7] (Fig. 1).
Case Presentation
We present an usual case of ovarian adenosquamous
carcinoma. A primary hospital referred a 57-year-old
Japanese woman (gravida 0, para 0) to our hospital
because a pelvic tumor was suspected. At the primary
hospital, the woman had complained of abdominal
fullness.
Fig. 1 A flow chart for the systematic review in this case report
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A cervical pap smear was negative for both intrae-
pithelial lesions and malignancy. Digital examination re-
vealed a mildly tender, mobile mass occupying most of
the lower abdomen. Magnetic resonance imaging
(Fig. 2a) conducted at the primary hospital and transva-
ginal ultrasound (Fig. 2b) revealed a pelvic tumor 14 cm
in diameter arising from the left adnexa. In addition, a
papillary nodule 4 cm in size was detected on the tumor
wall, which was suggestive of malignancy (Fig. 2c). There
was no clinical evidence of ascites. The tumor marker pro-
file was as follows: CA125, 42.6 U/mL; CA19-9, 134.1 U/
mL; CEA, 0.9 ng/mL; and SCC, 1.6 ng/mL. We therefore
suspected ovarian cancer and performed laparotomy.
During longitudinal laparotomy, we detected a left ovar-
ian tumor 14 cm in size and a small amount of yellow
transparent ascitic fluid in the abdominal cavity. Fluid
samples were submitted for cytology, left salpingo-
oophorectomy was performed, and biopsy samples were
obtained and frozen. The cytology of the ascitic fluid sug-
gested squamous cell carcinoma, while the biopsy indi-
cated adenosquamous carcinoma. Ovarian cancer was
diagnosed, and the patient underwent total abdominal
hysterectomy, right salpingo-oophorectomy, pelvic lymph
node dissection, para-aortic lymph node biopsy, and
total omentectomy.
Pathological examination revealed endometrioid adeno-
carcinoma with squamous differentiation. Grossly, the
excised specimen was unilocular and thin-walled and con-
tained a serous, yellow transparent fluid. There was a pap-
illary nodule in the wall of the left adnexa (Fig. 3a) and
multiple uterine myomas (Fig. 3b). However, the gross
findings showed no evidence of malignancy in the right
adnexa (Fig. 3b), omentum, or lymph nodes. There were
no concomitant teratomas or any features suggestive of
endometriosis.
Histologically, the endometrioid adenocarcinoma
(Fig. 4a) and squamous cell carcinoma (Fig. 4b) compo-
nents of the tumor were intermixed, with each compris-
ing approximately half of the tumor. Differentiation
from endometrioid adenocarcinoma to squamous cell
adenocarcinoma was also observed (Fig. 4c). Cytological
examination of the ascitic fluid revealed malignant squa-
mous cells (Fig. 4d) but no adenocarcinoma cells. The
uterus, right adnexa, omentum, and lymph nodes had no
malignant components (24 pelvic lymph nodes and 11
para-aortic lymph nodes were examined). There was no
evidence of a teratoma or endometriosis in the excised tis-
sue. The surgical stage was International Federation of
Gynecology and Obstetrics (FIGO) stage Ic (2).
The postoperative recovery was unremarkable. The
levels of all tumor markers were within the normal
range immediately after surgery. The patient received
6 cycles of paclitaxel (175 mg/m2) and carboplatin (area
under the curve, 6 mg/mL per min) every 3 weeks. In
the five and a half years since chemotherapy, she has
remained recurrence-free.
Results
The results of the systematic literature review are shown
in Table 1. The cases selected from those reviewed de-
scribed the clinical features of 8 patients (age range: 32–
57 years, median age: 49.5 years) with adenosquamous
carcinoma (4 arising from a mature cystic teratoma, 3
developing from endometriosis, and 1 described as a
pure adenosquamous carcinoma). FIGO stages were re-
ported in 6 of the 8 cases: stage I in 4 cases, stage III in
1 case, and stage IV in 1 case. Postoperative chemother-
apy was performed in 4 of the 8 cases, and all regimens
were platinum-based. In the 5 patients wherein the out-
come was assessed, the median overall survival time was
12 months (range: 3–36 months), and 4 of the 5 patients
showed recurrence.
Discussion
Many types of malignant tumors occur in the ovaries.
The most common primary malignant ovarian tumors
are adenocarcinomas, whereas squamous cell carcin-
omas are rare and adenosquamous carcinomas are even
rarer. Most reported squamous cell carcinomas presum-
ably originated from benign cystic teratomas [8] or
Brenner tumors [9]. There are few reports of pure squa-
mous cell carcinomas of the ovary [10].
Ovarian endometriosis is a frequent cause of squa-
mous cell carcinoma [11]. Endometrioid adenocarcin-
omas contain squamous elements and were previously
classified as adenoacanthomas or adenosquamous car-
cinomas depending on whether the squamous element
was benign or malignant, respectively. They have more
recently been termed “endometrioid adenocarcinomas
with squamous differentiation” [12].
The tumor in our case was composed of intermixed
endometrioid adenocarcinoma and squamous cell carcin-
oma components in almost equal parts. Differentiation of
the endometrioid adenocarcinoma component from the
squamous cell component was also observed. We there-
fore believe that the endometrioid adenocarcinoma devel-
oped first, after which squamous metaplasia led to the
formation of the squamous cell carcinoma. It seems rea-
sonable to describe this case as an adenosquamous carcin-
oma rather than an endometrioid adenocarcinoma with
squamous differentiation because nearly half of the tumor
consisted of malignant squamous cells. In support, in the
76 cases recently revaluated by Lim, squamous differenti-
ation was observed in 50 cases (76 %) [13].
Cytological examination of the ascitic fluid from pa-
tients with ovarian cancer usually reveals adenocarcinoma
cells. Most previous reports of ovarian adenosquamous
carcinomas did not discuss the cytology of the ascitic
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Fig. 2 a Sagittal section of T2 MRI revealed a unilocular cystic tumor measuring 14 cm in diameter. There is a papillary nodule (red allow) in the
tumor wall. b Transvaginal ultrasound revealed a unilocular cystic tumor measuring 14 cm in diameter. c Transvaginal ultrasound revealed a
papillary nodule measuring 4 cm in the tumor wall
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fluid, presumably because most cytological examinations
indicate adenocarcinoma. One report, however, did note
the presence of numerous clusters of adenocarcinoma
cells and a few squamous cells in the ascitic fluid [14]. In
contrast, in our case, the ascitic fluid contained malignant
squamous cells but not adenocarcinoma cells, perhaps be-
cause squamous cell carcinoma was the predominant
component of the tumor. This observation strongly sug-
gests that the squamous cell carcinoma component arose
from the adenocarcinoma component.
Although the prognosis of patients with adenosqua-
mous carcinoma merits discussion, the low number of
reported cases limits such discussion. The reported 5-
year survival rate was 90 % for patients with stage I or II
endometrioid adenoacanthoma, but was only 36 % for
patients with stage I or II endometrioid adenocarcinoma
[15]. Furthermore, of the 7 reported patients with ade-
nosquamous carcinomas arising from benign cystic tera-
tomas, the 3 with stage Ia disease remained alive and
recurrence-free for 9 months to 5 years after surgery,
while the 4 with stage Ic disease were resistant to ther-
apy and died within 13 months [2]. Karateke described a
patient with stage Ic adenosquamous carcinoma who re-
lapsed 13 months after surgery [6]. These outcome
Fig. 3 Macroscopic findings. a The excised ovarian tumor was unilocular and thin-walled with serous and yellow transparent fluid inside. There
was a papillary nodule on the tumor wall. b There were numerous uterine myomas. The uterus and right adnexa showed no gross findings
suggestive of malignancy
Shoji et al. Journal of Ovarian Research  (2016) 9:48 Page 5 of 7
results indicate that adenosquamous carcinoma has a
very poor prognosis and that clinical stage is an import-
ant determinant of outcome.
No effective treatments for adenosquamous carcinoma
have yet been established. We administered paclitaxel
and carboplatin because they are the standard chemo-
therapeutic agents for ovarian endometrioid adenocar-
cinoma and squamous cell carcinoma, respectively.
Since her first treatment, the patient in our case has
remained alive without recurrence for 66 months.
Table 1 Previously reported cases with adenosquamous carcinoma of the ovary
Author/year Ref. Age Origin Stage Adjuvant therapy Prognosis
Maeyama (1983) [3] 51 Mature cystic teratoma Ib Carboquone + Futraful Died 6 months
Iwaoki (1994) [2] 57 Mature cystic teratoma Ia CDDP + Epi + CPA Alive well 3 years
Hsu (1996) [5] 49 Mature cystic teratoma I NR Alive well 11 months
Karateke (2006) [6] 40 Mature cystic teratoma Ic No therapy Recurrence 12 months
Moguel (1992) [7] 50 Endometriosis IIIc CDDP + 5-Fu NR
Terada (2009) [4] 38 Endometriosis NR NR NR
Terada (2009) [4] 53 Endometriosis NR NR NR
Lee (2010) [1] 32 PureASC IV PTX-CBDCA Died 3 months
Oue case 57 Endometrioid adenocarcinoma Ic PTX-CBDCA Alive well 5.5 years
ASC adenosquamous carcinoma, PTX Paclitaxel, CBDCA Carboplatin, CDDP Cisplatin, Epi Epirubicin, CPA Cyclophosphamide, NR Not recorded
Fig. 4 a Adenocarcinoma cells with glandular formation and agglutination are observed. (Hematoxylin & Eosin staining × 100). b Intercellular
bridges are observed in cancer cells with solid growth. The tumor was diagnosed as squamous cell carcinoma. (Hematoxylin & Eosin staining × 100).
c A transition between adenocarcinoma and squamous cell carcinoma can be seen. This strongly suggests that the squamous cell carcinoma had
arisen from adenocarcinoma. (Hematoxylin & Eosin staining × 100). d Atypical cells are polygonal and strongly stained with orange G, indicating
nuclear concentration. These findings suggest the cells to be atypical and to be derived from squamous cell carcinoma. (Papanicolaou staining × 100)
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Despite the reportedly poor prognosis of patients with
adenosquamous carcinomas, chemotherapy consisting of
paclitaxel and carboplatin was effective in our case and
merits further study.
Because ovarian adenosquamous carcinomas are ex-
tremely rare, effective chemotherapeutic regimens should
be established once sufficient numbers of patients can be
recruited for statistical analysis. We hope that inter-
national organizations such as the Gynecologic Oncology
Group will aid in this endeavor.
Conclusions
We presented a rare case of an ovarian adenosquamous
carcinoma in which the squamous cell carcinoma com-
ponent originated from the endometrioid adenocarcin-
oma component. Histologically, the 8 adenosquamous
carcinomas reported in the literature arose from either
the mature cystic teratoma (4 cases) or endometriosis (3
cases) or were pure adenosquamous carcinomas (1 case).
To our knowledge, we are the first report a case of an
ovarian tumor consisting of intermixed squamous cell
carcinoma and endometrioid adenocarcinoma compo-
nents. Because there is no established chemotherapy
regimen for adenosquamous carcinoma, we adminis-
tered the agents (paclitaxel and carboplatin) routinely
used to treat epithelial ovarian cancers to our patient.
Although ovarian adenosquamous carcinoma is rare, ef-
forts should be made to recruit a sufficient number of
patients for clinical trials aimed at identifying effective
treatment protocols.
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